Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Medtronic has reported late-breaking data from the Evolut Low Risk Trial’s five-year outcomes of the Evolut TAVR system.

Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients: Galway, Ireland Tuesday, April 1 ...

Medtronic (NYSE:MDT) recently saw a substantial price movement, climbing 10% over the last quarter. This period was marked by ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

Medtronic plc’s Evolut Low-Risk trial continued to show non-inferiority of transcatheter aortic valve replacement to surgical ...

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...

Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...

Medtronic plc , a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evoluttm ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...